In a randomized , open-label , multicenter , phase III study , patients with previously untreated predominantly clear-cell mRCC were randomly assigned , stratified by prior nephrectomy and Memorial Sloan-Kettering Cancer Center prognostic group , to receive the combination of either temsirolimus ( 25 mg intravenously , weekly ) or IFN ( 9 MIU subcutaneously thrice weekly ) with bevacizumab ( 10 mg/kg intravenously , every 2 weeks ) .